A prostate cancer vaccine test showed encouraging results last month. Inovio Pharmaceuticals, based out of Washington, D.C., announced in June that its DNA vaccine for prostate cancer demonstrated a significant immune response in monkeys. The company plans to start a Phase I clinical trial in 2012.
The development of a prostate cancer vaccine is still far away, and patients need to find help in the meantime. Here at Chicago Prostate Center, we encourage men over the age of 50 (40 years old if you have a family history or are African American) to get yearly prostate cancer screenings that include a PSA test and digital rectal exam (DRE). Early detection is extremely important to curing prostate cancer. Contact us today to find out more and make an appointment for a screening at CPC.